memantine has been researched along with Idiopathic Parkinson Disease in 58 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Memantine, an uncompetitive antagonist of N-methyl-d-aspartate receptors, may have a role in managing symptoms associated with dementia in Parkinson's disease (PDD), although its role in improving patient-reported outcomes (PROs) has not been extensively investigated." | 9.19 | Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia. ( Atkinson, R; Leroi, I; Overshott, R, 2014) |
| "To investigate the effect on survival of treatment with memantine in patients with dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD)." | 9.19 | Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. ( Aarsland, D; Ballard, C; Larsson, V; Londos, E; Minthon, L; Stubendorff, K, 2014) |
| "To investigate quality of life (QOL) and the effect of memantine treatment in patients with Lewy body dementias." | 9.15 | Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson's disease dementia. ( Aarsland, D; Engedal, K; Larsson, V; Londos, E; Minthon, L; Wattmo, C, 2011) |
| "Previous studies have suggested that patients with Lewy-body-related dementias might benefit from treatment with the N-methyl D-aspartate receptor antagonist memantine, but further data are needed." | 9.14 | Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. ( Bladström, A; Bonuccelli, U; Ceballos-Baumann, A; Destée, A; Emre, M; Jones, R; Kutzelnigg, A; Tolosa, E; Tsolaki, M; Zdravkovic, S, 2010) |
| "This study addresses the effects of 52 weeks of treatment with the NMDA glutamate receptor antagonist memantine on motor, cognitive, and mental disorders in patients with Parkinson's disease complicated by dementia, as compared with a control group of patients not treated with memantine." | 9.14 | Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia. ( Litvinenko, IV; Mogil'naya, VI; Odinak, MM; Perstnev, SV, 2010) |
| "The objective of this study is to investigate the safety and tolerability of memantine, a glutamatergic modulator, in patients suffering from dementia associated with Parkinson's disease (PDD), an increasingly common complication of PD." | 9.14 | Randomized controlled trial of memantine in dementia associated with Parkinson's disease. ( Burns, A; Byrne, EJ; Daniel, E; Leroi, I; Overshott, R, 2009) |
| "Memantine (M) was used in the treatment of patients with Parkinson's disease (PD) with dementia." | 9.13 | [Efficacy of memantine in Parkinson's disease with dementia]. ( Batukaeva, LA; Levin, OS, 2008) |
| "To evaluate the effects of withdrawal or continuation of cholinesterase inhibitors or memantine, or both, in people with dementia on: cognitive, neuropsychiatric and functional outcomes, rates of institutionalisation, adverse events, dropout from trials, mortality, quality of life and carer-related outcomes." | 9.12 | Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. ( Hughes, C; Lim, WY; Loy, C; McGuinness, B; Parsons, C; Passmore, P; Ward, SA, 2021) |
| "The study has investigated the effect of NMDA-glutamate receptor antagonist memantine in the 52-weeks therapy of 32 PD patients with dementia (PDD) compared with the control group (30 cases)." | 7.74 | [Memantine (akatinol) therapy of cognitive impairment in Parkinson's disease complicated by dementia]. ( Litvinenko, IV; Mogil'naia, VI; Odinak, MM; Perstenev, SV, 2008) |
| "Memantine hydrochloride is a first-line therapeutic drug approved by the US Food and Drug Administration for the management of moderate to severe Alzheimer's disease (AD)." | 6.49 | Memantine hydrochloride in the treatment of dementia subtypes. ( Peng, D; Yuan, X; Zhu, R, 2013) |
| "Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find protective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection." | 5.56 | Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. ( Grieb, P; Rejdak, K, 2020) |
| "After some years with Parkinson's disease patients tend to develop fluctuating symptoms and dyskinesia with involuntary movements--a state difficult to manage." | 5.32 | [Memantine can relieve certain symptoms in Parkinson disease. Improvement achieved in two out of three described cases with dyskinesia and cognitive failure]. ( Lökk, J, 2004) |
| "Memantine, an uncompetitive antagonist of N-methyl-d-aspartate receptors, may have a role in managing symptoms associated with dementia in Parkinson's disease (PDD), although its role in improving patient-reported outcomes (PROs) has not been extensively investigated." | 5.19 | Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia. ( Atkinson, R; Leroi, I; Overshott, R, 2014) |
| "To investigate the effect on survival of treatment with memantine in patients with dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD)." | 5.19 | Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. ( Aarsland, D; Ballard, C; Larsson, V; Londos, E; Minthon, L; Stubendorff, K, 2014) |
| "To investigate quality of life (QOL) and the effect of memantine treatment in patients with Lewy body dementias." | 5.15 | Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson's disease dementia. ( Aarsland, D; Engedal, K; Larsson, V; Londos, E; Minthon, L; Wattmo, C, 2011) |
| "Memantine was well tolerated in PD; however, specific measures of sleepiness, fatigue, depression, and attention did not significantly improve." | 5.15 | Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial. ( Davidson, A; Lai, D; Ondo, WG; Shinawi, L, 2011) |
| "Previous studies have suggested that patients with Lewy-body-related dementias might benefit from treatment with the N-methyl D-aspartate receptor antagonist memantine, but further data are needed." | 5.14 | Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. ( Bladström, A; Bonuccelli, U; Ceballos-Baumann, A; Destée, A; Emre, M; Jones, R; Kutzelnigg, A; Tolosa, E; Tsolaki, M; Zdravkovic, S, 2010) |
| "This study addresses the effects of 52 weeks of treatment with the NMDA glutamate receptor antagonist memantine on motor, cognitive, and mental disorders in patients with Parkinson's disease complicated by dementia, as compared with a control group of patients not treated with memantine." | 5.14 | Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia. ( Litvinenko, IV; Mogil'naya, VI; Odinak, MM; Perstnev, SV, 2010) |
| "The objective of this study is to investigate the safety and tolerability of memantine, a glutamatergic modulator, in patients suffering from dementia associated with Parkinson's disease (PDD), an increasingly common complication of PD." | 5.14 | Randomized controlled trial of memantine in dementia associated with Parkinson's disease. ( Burns, A; Byrne, EJ; Daniel, E; Leroi, I; Overshott, R, 2009) |
| "Memantine (M) was used in the treatment of patients with Parkinson's disease (PD) with dementia." | 5.13 | [Efficacy of memantine in Parkinson's disease with dementia]. ( Batukaeva, LA; Levin, OS, 2008) |
| "To evaluate the effects of withdrawal or continuation of cholinesterase inhibitors or memantine, or both, in people with dementia on: cognitive, neuropsychiatric and functional outcomes, rates of institutionalisation, adverse events, dropout from trials, mortality, quality of life and carer-related outcomes." | 5.12 | Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. ( Hughes, C; Lim, WY; Loy, C; McGuinness, B; Parsons, C; Passmore, P; Ward, SA, 2021) |
| "The aim of this article is to discuss new data on presently approved drugs for dementia, such as cholinesterase inhibitors and memantine, and concerns regarding the use of antipsychotics for treating neuropsychiatric symptoms, as well as to summarize some relevant studies recently published on emerging therapies with potential disease-modifying effects." | 4.83 | Treatment of dementia: anything new? ( Caramelli, P; Machado, JC, 2006) |
| "The study has investigated the effect of NMDA-glutamate receptor antagonist memantine in the 52-weeks therapy of 32 PD patients with dementia (PDD) compared with the control group (30 cases)." | 3.74 | [Memantine (akatinol) therapy of cognitive impairment in Parkinson's disease complicated by dementia]. ( Litvinenko, IV; Mogil'naia, VI; Odinak, MM; Perstenev, SV, 2008) |
| "Mild cognitive impairment in Parkinson's disease (PD-MCI) is associated with an increased risk of cognitive decline." | 3.11 | Memantine for the patients with mild cognitive impairment in Parkinson's disease: a pharmacological fMRI study. ( Kawashima, S; Matsukawa, N, 2022) |
| "Memantine was well tolerated, without any serious adverse events, or worsening in the parkinsonian motor score." | 2.82 | Memantine and reduced time with dyskinesia in Parkinson's Disease. ( Wictorin, K; Widner, H, 2016) |
| "A randomised double-blind, placebo-controlled, 24-week three centre trial of memantine (20 mg/day) was conducted in which tests of attention (simple and choice reaction time) and word recognition (immediate and delayed) from the CDR System were administered prior to dosing and again at 12 and 24 weeks." | 2.80 | Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. ( Aarsland, D; Ballard, C; Londos, E; Wesnes, KA, 2015) |
| "Memantine treatment was associated with lower axial motor symptom and dyskinesia scores but did not improve gait." | 2.78 | Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study. ( Allorge, D; Blum, D; Bordet, R; Defebvre, L; Delval, A; Destée, A; Devos, D; Duhamel, A; Dujardin, K; Hossein-Foucher, C; Moreau, C; Petyt, G; Sablonnière, B; Schraen, S; Tiffreau, V, 2013) |
| "Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are common forms of dementia that substantially affect quality of life." | 2.74 | Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. ( Aarsland, D; Alves, G; Ballard, C; Bostrom, F; Kossakowski, K; Leroi, I; Londos, E; Minthon, L; Pozo-Rodriguez, F; Walker, Z, 2009) |
| "Whilst dementia has long been synonymous with AD, it is becoming more widely accepted as part of the clinical spectrum in PD (PDD)." | 2.53 | Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia. ( Lewis, SJ; Szeto, JY, 2016) |
| "Parkinson's disease is the second most frequent neurodegenerative disorder." | 2.52 | Cognitive impairment in Parkinson's disease. ( Ransmayr, G, 2015) |
| " Additionally, both of them had good safety outcomes, although rivastigmine showed an increased risk on adverse events than placebo (risk ratio, RR 1." | 2.52 | Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. ( Jiang, T; Meng, XF; Tan, CC; Tan, L; Tan, MS; Tang, SW; Wang, C; Wang, HF; Yu, JT, 2015) |
| "Memantine hydrochloride is a first-line therapeutic drug approved by the US Food and Drug Administration for the management of moderate to severe Alzheimer's disease (AD)." | 2.49 | Memantine hydrochloride in the treatment of dementia subtypes. ( Peng, D; Yuan, X; Zhu, R, 2013) |
| "Although Parkinson's disease (PD) has been considered to primarily affect motor abilities, increasing emphasis is being placed on cognitive and behavioural impairment in this disorder." | 2.44 | Cognitive and behavioural impairment in Parkinson's disease. ( Freedman, M; Merims, D, 2008) |
| "It is essential to recognize and treat psychosis in Parkinson's disease for several reasons." | 2.44 | Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective? ( Fernandez, HH; Zahodne, LB, 2008) |
| "Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find protective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection." | 1.56 | Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. ( Grieb, P; Rejdak, K, 2020) |
| "The new dry syrup formulation containing memantine hydrochloride showed bioequivalence to the film-coated tablet under the two dosing conditions." | 1.51 | Pharmacokinetics and Bioequivalence of Memantine Tablet and a New Dry Syrup Formulation in Healthy Japanese Males: Two Single-Dose Crossover Studies. ( Hasegawa, S; Ishizuka, H; Ishizuka, T; Maekawa, Y; Shiosakai, K, 2019) |
| "Dementia with Lewy bodies and Parkinson's disease with dementia should be treated with rivastigmine." | 1.35 | [Treatment of degenerative dementia disorders--who should be treated?]. ( Hasselbalch, SG; Kampmann, JP, 2009) |
| "The degree of severity of Parkinson's disease (PD) according to the Hoehn and Yahr scale was 2." | 1.34 | [Akatinol memantine in the therapy of cognitive disorders in Parkinson's disease]. ( Kozhevnikova, ZhV; Krivonos, OV; Puzin, MN, 2007) |
| "After some years with Parkinson's disease patients tend to develop fluctuating symptoms and dyskinesia with involuntary movements--a state difficult to manage." | 1.32 | [Memantine can relieve certain symptoms in Parkinson disease. Improvement achieved in two out of three described cases with dyskinesia and cognitive failure]. ( Lökk, J, 2004) |
| "Some treatments used for Parkinson's disease attenuate locomotor depression in rats treated with reserpine and alpha-methyl-p-tyrosine." | 1.29 | Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats. ( Danysz, W; Quack, G; Rogoz, Z; Skuza, G, 1994) |
| "Memantine is a 1-amino-adamantane derivative which has been proposed to be useful in the treatment of Parkinson's disease." | 1.28 | Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. ( Korczyn, AD; Nissipeanu, P; Rabey, JM, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (6.90) | 18.7374 |
| 1990's | 4 (6.90) | 18.2507 |
| 2000's | 15 (25.86) | 29.6817 |
| 2010's | 28 (48.28) | 24.3611 |
| 2020's | 7 (12.07) | 2.80 |
| Authors | Studies |
|---|---|
| Duque, MD | 1 |
| Camps, P | 1 |
| Torres, E | 1 |
| Valverde, E | 1 |
| Sureda, FX | 1 |
| López-Querol, M | 1 |
| Camins, A | 1 |
| Prathalingam, SR | 1 |
| Kelly, JM | 1 |
| Vázquez, S | 1 |
| Radulović, S | 1 |
| Sunkara, S | 1 |
| Maurer, C | 1 |
| Leitinger, G | 1 |
| Kawashima, S | 1 |
| Matsukawa, N | 1 |
| Parsons, C | 1 |
| Lim, WY | 1 |
| Loy, C | 1 |
| McGuinness, B | 1 |
| Passmore, P | 1 |
| Ward, SA | 1 |
| Hughes, C | 1 |
| Müller, T | 1 |
| Riederer, P | 3 |
| Kuhn, W | 1 |
| Maekawa, Y | 1 |
| Hasegawa, S | 1 |
| Ishizuka, T | 1 |
| Shiosakai, K | 1 |
| Ishizuka, H | 1 |
| Rejdak, K | 1 |
| Grieb, P | 1 |
| Giebel, C | 1 |
| Cations, M | 1 |
| Draper, B | 1 |
| Komuravelli, A | 1 |
| Huang, C | 1 |
| Zhao, S | 1 |
| Cheng, B | 1 |
| Chen, G | 1 |
| Pan, J | 1 |
| Miliukhina, IV | 1 |
| Gracheva, EV | 1 |
| Ahn, BJ | 1 |
| Kwon, KY | 1 |
| Roeben, B | 1 |
| Zieschang, T | 1 |
| Maetzler, W | 1 |
| van de Glind, EM | 1 |
| van Enst, WA | 1 |
| van Munster, BC | 1 |
| Olde Rikkert, MG | 1 |
| Scheltens, P | 1 |
| Scholten, RJ | 1 |
| Hooft, L | 1 |
| Peng, D | 1 |
| Yuan, X | 1 |
| Zhu, R | 1 |
| Leroi, I | 3 |
| Atkinson, R | 1 |
| Overshott, R | 2 |
| Wesnes, KA | 1 |
| Aarsland, D | 8 |
| Ballard, C | 6 |
| Londos, E | 6 |
| Wang, HF | 1 |
| Yu, JT | 1 |
| Tang, SW | 1 |
| Jiang, T | 1 |
| Tan, CC | 1 |
| Meng, XF | 1 |
| Wang, C | 1 |
| Tan, MS | 1 |
| Tan, L | 1 |
| Stubendorff, K | 1 |
| Larsson, V | 3 |
| Minthon, L | 5 |
| Wictorin, K | 1 |
| Widner, H | 1 |
| Ransmayr, G | 1 |
| Szeto, JY | 1 |
| Lewis, SJ | 1 |
| Merims, D | 1 |
| Freedman, M | 1 |
| Litvinenko, IV | 2 |
| Odinak, MM | 2 |
| Mogil'naia, VI | 1 |
| Perstenev, SV | 1 |
| Levin, OS | 1 |
| Batukaeva, LA | 1 |
| Hasselbalch, SG | 1 |
| Kampmann, JP | 1 |
| Byrne, EJ | 1 |
| Daniel, E | 1 |
| Burns, A | 1 |
| Emre, M | 2 |
| Walker, Z | 1 |
| Bostrom, F | 1 |
| Alves, G | 1 |
| Kossakowski, K | 1 |
| Pozo-Rodriguez, F | 1 |
| Varanese, S | 1 |
| Howard, J | 1 |
| Di Rocco, A | 1 |
| Mogil'naya, VI | 1 |
| Perstnev, SV | 1 |
| Kassubek, J | 1 |
| Büttner, T | 1 |
| Reichmann, H | 1 |
| Schulz, JB | 1 |
| Wüllner, U | 1 |
| Csoti, I | 1 |
| Yeh, HH | 1 |
| Yang, YH | 1 |
| Chen, SH | 1 |
| Johansson, C | 1 |
| Hansson, O | 1 |
| Palmqvist, S | 1 |
| Tsolaki, M | 1 |
| Bonuccelli, U | 1 |
| Destée, A | 2 |
| Tolosa, E | 1 |
| Kutzelnigg, A | 1 |
| Ceballos-Baumann, A | 1 |
| Zdravkovic, S | 1 |
| Bladström, A | 1 |
| Jones, R | 1 |
| Ondo, WG | 1 |
| Shinawi, L | 1 |
| Davidson, A | 1 |
| Lai, D | 1 |
| Li, W | 1 |
| Zhao, JH | 1 |
| Sun, SG | 1 |
| Zhang, JW | 1 |
| Suo, AQ | 1 |
| Ma, MM | 1 |
| Olivares, D | 1 |
| Deshpande, VK | 1 |
| Shi, Y | 1 |
| Lahiri, DK | 1 |
| Greig, NH | 1 |
| Rogers, JT | 1 |
| Huang, X | 1 |
| Engedal, K | 1 |
| Wattmo, C | 1 |
| Rongve, A | 1 |
| Broadstock, M | 1 |
| Svenningsson, P | 1 |
| Moreau, C | 1 |
| Delval, A | 1 |
| Tiffreau, V | 1 |
| Defebvre, L | 1 |
| Dujardin, K | 1 |
| Duhamel, A | 1 |
| Petyt, G | 1 |
| Hossein-Foucher, C | 1 |
| Blum, D | 1 |
| Sablonnière, B | 1 |
| Schraen, S | 1 |
| Allorge, D | 1 |
| Bordet, R | 1 |
| Devos, D | 1 |
| Vidal, EI | 1 |
| Fukushima, FB | 1 |
| Valle, AP | 1 |
| Villas Boas, PJ | 1 |
| Lökk, J | 1 |
| Machado, JC | 1 |
| Caramelli, P | 1 |
| Johannsen, P | 1 |
| Puzin, MN | 1 |
| Krivonos, OV | 1 |
| Kozhevnikova, ZhV | 1 |
| Alisky, JM | 1 |
| Gallini, A | 1 |
| Sommet, A | 1 |
| Salandini, AM | 1 |
| Veyssière, P | 1 |
| Montastruc, JL | 2 |
| Borghammer, P | 1 |
| Vafaee, M | 1 |
| Ostergaard, K | 1 |
| Rodell, A | 1 |
| Bailey, C | 1 |
| Cumming, P | 1 |
| Zahodne, LB | 1 |
| Fernandez, HH | 1 |
| Schneider, E | 2 |
| Fischer, PA | 2 |
| Clemens, R | 1 |
| Balzereit, F | 1 |
| Fünfgeld, EW | 2 |
| Haase, HJ | 1 |
| Wesemann, W | 2 |
| Sturm, G | 1 |
| Skuza, G | 1 |
| Rogoz, Z | 1 |
| Quack, G | 1 |
| Danysz, W | 1 |
| Jacobi, P | 1 |
| Schönberger, B | 1 |
| Costall, B | 1 |
| Naylor, RJ | 1 |
| Rabey, JM | 1 |
| Nissipeanu, P | 1 |
| Korczyn, AD | 1 |
| Lange, KW | 1 |
| Kornhuber, J | 1 |
| Danielczyk, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Memantine for Enhanced Stroke Recovery[NCT02144584] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2014-01-31 | Active, not recruiting | ||
| A Randomised, Double-blind, Placebo-controlled, 6-month Study of the Efficacy and Safety of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies[NCT00855686] | Phase 4 | 199 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A 16 Week, Investigator-initiated, Single-center, Double Blind, Randomized, Placebo-controlled Trial of Namenda® (Memantine Hcl) for Non-motor Symptoms in Parkinson's Disease[NCT00646204] | Phase 4 | 40 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| The Effect of High Frequency Repetitive Transcranial Magnetic Stimulation on Cognitive Impairment in Parkinson's Disease[NCT03879551] | 30 participants (Actual) | Interventional | 2019-03-15 | Completed | |||
| Study of Memantine to Treat Gait Disorders And Attention Deficit In Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Monocentric Trial[NCT01108029] | Phase 4 | 28 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability: A Randomized, Double-Blind, Placebo-Controlled Trial[NCT00627250] | 76 participants (Actual) | Interventional | 2003-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change from baseline to end of study in the following assessment: global tremor assessment by examiner. The maximum total score is 48 and would indicate a high prevalence of tremor. The minimum total score is 0 and would indicate no tremor. (NCT00646204)
Timeframe: Baseline and 16 weeks
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| Baseline | 16 Weeks | |
| Memantine-1 | 2.8 | 2.8 |
| Placebo-2 | 2.8 | 2.8 |
Assess the overall change from baseline in ON state motor United Parkinson Disease Rating scale (UPDRS) scores as assessed in the scale. The minimum score is 0 and the maximum score 199. The maximum score of 199 means the worst possible disability from Parkinson's Disease. (NCT00646204)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Before treatment | After treatment | |
| Memantine-1 | 12 | 10 |
| Placebo-2 | 12 | 10 |
15 reviews available for memantine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Digging Deeper: Advancements in Visualization of Inhibitory Synapses in Neurodegenerative Disorders.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Brain; Humans; Huntington Disease; Levodo | 2021 |
Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Human | 2021 |
Pharmacological treatment of dementia: a scoping review of systematic reviews.
Topics: Aged; Aged, 80 and over; Behavior; Cholinesterase Inhibitors; Cognition Disorders; Data Interpretati | 2013 |
Memantine hydrochloride in the treatment of dementia subtypes.
Topics: Alzheimer Disease; Dementia; Excitatory Amino Acid Antagonists; Humans; Memantine; Parkinson Disease | 2013 |
Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis.
Topics: Antiparkinson Agents; Cholinesterase Inhibitors; Cognition Disorders; Humans; Lewy Body Disease; Mem | 2015 |
Cognitive impairment in Parkinson's disease and dementia with Lewy bodies.
Topics: Animals; Cholinesterase Inhibitors; Cognition Disorders; Humans; Lewy Body Disease; Memantine; Parki | 2016 |
Cognitive impairment in Parkinson's disease.
Topics: Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Humans; Memantine; Muscle Rigidity; Par | 2015 |
Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Cognitive Behavioral Th | 2016 |
Cognitive and behavioural impairment in Parkinson's disease.
Topics: Antiparkinson Agents; Cognition Disorders; Dementia; Disease Progression; Humans; Incidence; Lewy Bo | 2008 |
[On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].
Topics: Amantadine; Excitatory Amino Acid Antagonists; Humans; Indans; Memantine; Monoamine Oxidase; Monoami | 2010 |
N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease.
Topics: Alzheimer Disease; Animals; Dementia, Vascular; Humans; Memantine; Neuroprotective Agents; Parkinson | 2012 |
Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia.
Topics: Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia; Humans; Lewy Body Disease; Memantine; | 2012 |
Treatment of dementia: anything new?
Topics: Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Dementia; Dopamine Agents; Human | 2006 |
[Medical treatment of Alzheimer's disease].
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; | 2006 |
Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective?
Topics: Antiparkinson Agents; Antipsychotic Agents; Cholinesterase Inhibitors; Clinical Trials as Topic; Dis | 2008 |
19 trials available for memantine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Memantine for the patients with mild cognitive impairment in Parkinson's disease: a pharmacological fMRI study.
Topics: Cognitive Dysfunction; Humans; Magnetic Resonance Imaging; Memantine; Neuropsychological Tests; Park | 2022 |
Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Caregivers; Cost of Illness; Dementia; Dopamine Agent | 2014 |
Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Attention; Cognition; Double-Bl | 2015 |
Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study.
Topics: Aged; Antiparkinson Agents; Dementia; Double-Blind Method; Female; Humans; Lewy Body Disease; Male; | 2014 |
Memantine and reduced time with dyskinesia in Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Excit | 2016 |
[Efficacy of memantine in Parkinson's disease with dementia].
Topics: Aged; Antiparkinson Agents; Dementia; Dose-Response Relationship, Drug; Female; Follow-Up Studies; H | 2008 |
Randomized controlled trial of memantine in dementia associated with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Dementia; Double-Blind Method; Drug Evaluation; Excitatory Amino Acid Antag | 2009 |
Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.
Topics: Aged; Aged, 80 and over; Brain; Cognition; Cognition Disorders; Double-Blind Method; Excitatory Amin | 2009 |
Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cognition; Cognition Disorders; Dementia; Di | 2010 |
Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment.
Topics: Aged; Aged, 80 and over; Dopamine Agents; Double-Blind Method; Female; Humans; Lewy Body Disease; Ma | 2011 |
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.
Topics: Accidental Falls; Aged; Aged, 80 and over; Dementia; Double-Blind Method; Europe; Female; Humans; In | 2010 |
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.
Topics: Accidental Falls; Aged; Aged, 80 and over; Dementia; Double-Blind Method; Europe; Female; Humans; In | 2010 |
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.
Topics: Accidental Falls; Aged; Aged, 80 and over; Dementia; Double-Blind Method; Europe; Female; Humans; In | 2010 |
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.
Topics: Accidental Falls; Aged; Aged, 80 and over; Dementia; Double-Blind Method; Europe; Female; Humans; In | 2010 |
The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia.
Topics: Aged; Aged, 80 and over; Dopamine Agents; Female; Humans; Lewy Body Disease; Male; Memantine; Outcom | 2010 |
Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial.
Topics: Aged; Antiparkinson Agents; Depression; Double-Blind Method; Fatigue; Female; Humans; Male; Memantin | 2011 |
[Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Female; Humans; Male; Memantine; Middle Aged; Parki | 2011 |
Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson's disease dementia.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Dementia; Diagnostic and Statistical Manual of Men | 2011 |
Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Disability Evaluation; Double-Blind Method; Dyskinesi | 2013 |
Effect of memantine on CBF and CMRO2 in patients with early Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain; Cerebrovascular Circulation; Female; Humans; Magnetic Resonance I | 2008 |
[Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study].
Topics: Administration, Oral; Aged; Amantadine; Clinical Trials as Topic; Female; Humans; Male; Memantine; M | 1984 |
[Effects of intravenous administration of memantine in parkinsonian patients (author's transl)].
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Female; Humans; Infusions, Parenteral; Male; Mema | 1977 |
24 other studies available for memantine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
New oxapolycyclic cage amines with NMDA receptor antagonist and trypanocidal activities.
Topics: Amines; Animals; Antiparkinson Agents; Cells, Cultured; Humans; Memantine; Molecular Structure; Neur | 2010 |
Aminoadamantanes: from treatment of Parkinson's and Alzheimer's disease to symptom amelioration of long COVID-19 syndrome?
Topics: Alzheimer Disease; Amantadine; COVID-19; Humans; Memantine; Parkinson Disease; Post-Acute COVID-19 S | 2023 |
Pharmacokinetics and Bioequivalence of Memantine Tablet and a New Dry Syrup Formulation in Healthy Japanese Males: Two Single-Dose Crossover Studies.
Topics: Adult; Antiparkinson Agents; Area Under Curve; Cross-Over Studies; Drug Compounding; Female; Healthy | 2019 |
Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Amantadine; Asymptomatic Infections; Betacoronavirus; Co | 2020 |
Ethnic disparities in the uptake of anti-dementia medication in young and late-onset dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cross-Sectional Studies; Dementia; Humans; Lewy Body D | 2023 |
Topics: Animals; Antiparkinson Agents; Biomechanical Phenomena; Biomimetics; Fractures, Stress; Gait; Humans | 2020 |
Elderly woman presenting with unusual propriospinal myoclonus triggered by drug-induced nausea and vomiting.
Topics: Aged, 80 and over; Alzheimer Disease; Bupropion; Dopamine Agents; Dopamine Uptake Inhibitors; Female | 2018 |
[Therapy of Dementia: State of the Art].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Humans; Memantine; Parkinson Disease; Risk F | 2018 |
[Memantine (akatinol) therapy of cognitive impairment in Parkinson's disease complicated by dementia].
Topics: Aged; Cognition; Cognition Disorders; Dementia; Dopamine Agents; Dose-Response Relationship, Drug; F | 2008 |
[Treatment of degenerative dementia disorders--who should be treated?].
Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Dementia; Dopamine Agents; | 2009 |
Memantine: a new hope for treatment of Lewy body-related dementias?
Topics: Aged; Brain; Brain Chemistry; Clinical Trials as Topic; Drug Interactions; Excitatory Amino Acid Ant | 2009 |
NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Incidence; Le | 2010 |
Simultaneous determination of memantine and amantadine in human plasma as fluorescein derivatives by micellar electrokinetic chromatography with laser-induced fluorescence detection and its clinical application.
Topics: Acetonitriles; Alzheimer Disease; Amantadine; Antiparkinson Agents; Chemical Fractionation; Chromato | 2010 |
Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia.
Topics: Aged, 80 and over; Antiparkinson Agents; Dementia; Dopamine Agents; Dyskinesia, Drug-Induced; Humans | 2013 |
[Memantine can relieve certain symptoms in Parkinson disease. Improvement achieved in two out of three described cases with dyskinesia and cognitive failure].
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Dopamine Agents; Dyskinesias; Female; Humans; Male; | 2004 |
[Akatinol memantine in the therapy of cognitive disorders in Parkinson's disease].
Topics: Antiparkinson Agents; Cognition; Cognition Disorders; Dose-Response Relationship, Drug; Drug Adminis | 2007 |
Successful treatment of Parkinson disease with memantine.
Topics: Aged; Antiparkinson Agents; Female; Humans; Memantine; Parkinson Disease; Patient Compliance | 2007 |
Weight-loss associated with anti-dementia drugs in a patient with Parkinson's disease.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Anorexia; Antiparkinson Agents; Cholinesterase Inhibi | 2007 |
Distribution of metabolism of the potential anti-parkinson drug memantine in the human.
Topics: Aged; Amantadine; Antiparkinson Agents; Brain Chemistry; Female; Humans; Memantine; Parkinson Diseas | 1980 |
Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats.
Topics: Amantadine; Animals; Bromocriptine; Dopamine; Drug Synergism; Levodopa; Male; Memantine; Motor Activ | 1994 |
Neuropharmacological studies on D145 (1,3-dimethyl-5-aminoadamantan).
Topics: Amantadine; Animals; Apomorphine; Behavior; Corpus Striatum; Dextroamphetamine; Dopamine; Extrapyram | 1975 |
Therapy of Morbus Parkinson and radical-induced neurotoxicity in the rat--in vivo voltammetric studies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson | 1992 |
Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease.
Topics: Aged; Female; Humans; Male; Memantine; Middle Aged; Parkinson Disease; Psychomotor Performance; Rece | 1992 |
Pharmacotoxic psychosis after memantine in Parkinson's disease.
Topics: Aged; Female; Humans; Male; Memantine; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced | 1991 |